Header Logo

James L Mulshine

TitleProfessor
InstitutionRush University, Rush Medical College
DepartmentInternal Medicine
Phone301-980-6787
ORCID ORCID Icon0000-0002-4648-9177 Additional info
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Other Appointments:
    Dean, Rush Graduate College (Acting)
    Vice President, Rush University Medical Center

    Overview:
    I have worked on translational research in lung cancer including prevention and biological-based biomarker development with multiple papers and patents related to this work over the last thirty five years. My primary interest has been in the management of early lung cancer. I have served on and chair a number of national and international research advisory boards co-chaired a panel to prioritize development of all relevant biomarkers used in the SPORE program in 2003. I started and led the Upper Aerodigestive Tumor Biology Faculty in the NCI Intramural Program. I have also been involved in technology development issues for many years and served on the NIH Director’s Tech Transfer Subcommittee for nine years while in Bethesda to provide advice on the approval of CRADAs for the intramural NIH programs. Have served as Associate Provost for Research at Rush University from 2005-2015, Acting Dean of the Rush Graduate College from 2012 to the present. Over much of that time, I had the lead responsibility for developing the appropriate infrastructural foundations for biomedical research and education at Rush and worked with the faculty to sustain a productive environment for research and faculty development. Initially my capacity as Associate Provost for Research, I have worked with Dr. Josh Jacobs and the leadership of the Rush research community as we have established a CTSA-like infrastructure funded by Rush institutional support. We worked with the leadership of the ITM over the last 5 years as an affiliate member and have harmonized our research infrastructure and key functions with the corresponding ITM processes. We are now well positioned to join in ITM 2.0 as a fully functional and complementary partner to University of Chicago in achieving the new vision and goals outlined in the current submission.

    This joint CTSA submission builds on the productive legacy of the PCORI collaboration in CAPriCORN which was led initially by David Meltzer of U of C and now by the Raj Shah of Rush. Other established areas of Rush/ University of Chicago are multiple but involvement in the community research consortium, C3 and the outcomes research consortium, Chicago Learn are two excellent examples of the ongoing success of the U of C/ Rush collaborations. Now over the last several years I have worked as the Acting Dean of the Graduate College and in that capacity have been involved in the planning of the training and mentoring activities proposed in the new CTSA application. Through considerable Rush institutional investment, we bring a totally reengineered Graduate college curriculum for translational research to the new ITM 2.0 effort. I have had a series of roles with ITM 1.0 and have worked to integrate the efforts of the ITM 2.0 with CAPriCORN in relevant setting in collaboration with Dr. Richard Kennedy by cross- walking the governance documents for the PCORI funded, CAPriCORN and the latest NCATS funding opportunity announcement to minimize administrative barriers to complementary activities.

    In my leadership role in the Graduate College at Rush, I have been responsible for a complete overhaul of the laboratory-based, PhD and Masters programs including implementing a new and sustainable funding model for Rush to greatly enhance its support of translational science PhD education. Supported by the medical bioinformatics faculty at Rush, we have introduced a new rapid learning/ big data course into the Masters of Sciences in Clinical Research curriculum to help our students in the transition to a population healthcare model. We co-developed with the other Chicago AMCs, a recent professional development forum with iBIO for graduate students and post-doctoral fellows in a series that we had previously hosted with the University of Illinois in Chicago. Going forward these events will be sponsored for all Chicago academic medical centers through an inclusive ITM/iBIO collaboration. I continue to maintain a research interest in the area of early lung cancer management especially as it related to quantitative imaging.



    My ORCID is 0000-0002-4648-9177.
    My Scopus is 24285376700.
    My NIH COMMONS name is Jmulshine.

    Education:
    BA 1974 College of the Holy Cross, Worcester (Biology)
    M.D. 1977 Loyola Stritch Medical School, Chicago (Medicine)
    Residency 1980 Cleveland Clinic Foundation, Cleveland (Internal Medicine)
    Fellowship 1983 National Cancer Institute, Bethesda (Medical Oncology)

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Lam S, Wynes MW, Connolly C, Ashizawa K, Atkar-Khattra S, Belani CP, DiNatale D, Henschke CI, Hochhegger B, Jacomelli C, Jelitto M, Jirapatnakul A, Kelly KL, Krishnan K, Kobayashi T, Logan J, Mattos J, Mayo J, McWilliams A, Mitsudomi T, Pastorino U, Polanska J, Rzyman W, Sales Dos Santos R, Scagliotti GV, Wakelee H, Yankelevitz DF, Field JK, Mulshine JL, Avila R. The International Association for the Study of Lung Cancer Early Lung Imaging Confederation Open-Source Deep Learning and Quantitative Measurement Initiative. J Thorac Oncol. 2024 Jan; 19(1):94-105. PMID: 37595684.
      Citations:    
    2. Avila RS, Fain SB, Hatt C, Armato SG, Mulshine JL, Gierada D, Silva M, Lynch DA, Hoffman EA, Ranallo FN, Mayo JR, Yankelevitz D, Estepar RSJ, Subramaniam R, Henschke CI, Guimaraes A, Sullivan DC. QIBA guidance: Computed tomography imaging for COVID-19 quantitative imaging applications. Clin Imaging. 2021 Sep; 77:151-157. PMID: 33684789.
      Citations:    
    3. Mulshine JL, Avila RS, Conley E, Devaraj A, Ambrose LF, Flanagan T, Henschke CI, Hirsch FR, Janz R, Kakinuma R, Lam S, McWilliams A, Van Ooijen PMA, Oudkerk M, Pastorino U, Reeves A, Rogalla P, Schmidt H, Sullivan DC, Wind HHJ, Wu N, Wynes M, Xueqian X, Yankelevitz DF, Field JK. The International Association for the Study of Lung Cancer Early Lung Imaging Confederation. JCO Clin Cancer Inform. 2020 02; 4:89-99. PMID: 32027538.
      Citations:    
    4. Mulshine JL, Ujhazy P, Antman M, Burgess CM, Kuzmin I, Bunn PA, Johnson BE, Roth JA, Pass HI, Ross SM, Aldige CR, Wistuba II, Minna JD. From clinical specimens to human cancer preclinical models-a journey the NCI-cell line database-25 years later. J Cell Biochem. 2019 Dec 05. PMID: 31803961.
      Citations:    
    5. Field JK, deKoning H, Oudkerk M, Anwar S, Mulshine J, Pastorino U, Eberhardt W, Prosch H. Implementation of lung cancer screening in Europe: challenges and potential solutions: summary of a multidisciplinary roundtable discussion. ESMO Open. 2019; 4(5):e000577. PMID: 31673428.
      Citations:    
    6. Mulshine JL. Status of lung cancer screening. J Thorac Dis. 2017 Nov; 9(11):4311-4314. PMID: 29266114.
      Citations:    
    7. Rydzak CE, Armato SG, Avila RS, Mulshine JL, Yankelevitz DF, Gierada DS. Quality assurance and quantitative imaging biomarkers in low-dose CT lung cancer screening. Br J Radiol. 2018 Oct; 91(1090):20170401. PMID: 28830225.
      Citations:    
    8. Sevick-Muraca EM, Frank RA, Giger ML, Mulshine JL. Moonshot Acceleration Factor: Medical Imaging. Cancer Res. 2017 11 01; 77(21):5717-5720. PMID: 28993413.
      Citations:    
    9. Soo RA, Stone ECA, Cummings KM, Jett JR, Field JK, Groen HJM, Mulshine JL, Yatabe Y, Bubendorf L, Dacic S, Rami-Porta R, Detterbeck FC, Lim E, Asamura H, Donington J, Wakelee HA, Wu YL, Higgins K, Senan S, Solomon B, Kim DW, Johnson M, Yang JCH, Sequist LV, Shaw AT, Ahn MJ, Costa DB, Patel JD, Horn L, Gettinger S, Peters S, Wynes MW, Faivre-Finn C, Rudin CM, Tsao A, Baas P, Kelly RJ, Leighl NB, Scagliotti GV, Gandara DR, Hirsch FR, Spigel DR. Scientific Advances in Thoracic Oncology 2016. J Thorac Oncol. 2017 08; 12(8):1183-1209. PMID: 28579481.
      Citations:    
    10. Rzyman W, Mulshine JL. Lung cancer screening moving forward. Ann Transl Med. 2016 Apr; 4(8):149. PMID: 27195267.
      Citations:    
    11. Mulshine JL, Gierada DS, Armato SG, Avila RS, Yankelevitz DF, Kazerooni EA, McNitt-Gray MF, Buckler AJ, Sullivan DC. Role of the Quantitative Imaging Biomarker Alliance in optimizing CT for the evaluation of lung cancer screen-detected nodules. J Am Coll Radiol. 2015 Apr; 12(4):390-5. PMID: 25842017.
      Citations:    
    12. Cummings KM, Dresler CM, Field JK, Fox J, Gritz ER, Hanna NH, Ikeda N, Jassem J, Mulshine JL, Peters MJ, Yamaguchi NH, Warren G, Zhou C. E-cigarettes and cancer patients. J Thorac Oncol. 2014 Apr; 9(4):438-41. PMID: 24736063.
      Citations:    
    13. Mulshine JL, Healton C. Tobacco control since the 1964 Surgeon General's Report: reflecting back and looking forward. Oncology (Williston Park). 2014 Mar; 28(3):180, 182-3, 210. PMID: 24855724.
      Citations:    
    14. Field JK, Aberle DR, Altorki N, Baldwin DR, Dresler C, Duffy SW, Goldstraw P, Hirsch FR, Pedersen JH, de Koning HJ, Mulshine JL, Sullivan DC, Tsao MS, Travis WD. The International Association Study Lung Cancer (IASLC) Strategic Screening Advisory Committee (SSAC) response to the USPSTF recommendations. J Thorac Oncol. 2014 Feb; 9(2):141-3. PMID: 24419409.
      Citations:    
    15. Fang C, Man YG, Cuttitta F, Stetler-Stevenson W, Salomon D, Mazar A, Kulesza P, Rosen S, Avital I, Stojadinovic A, Jewett A, Jiang B, Mulshine J. Novel Phenotypic Fluorescent Three-Dimensional Co-Culture Platforms for Recapitulating Tumor in vivo Progression and for Personalized Therapy. J Cancer. 2013; 4(9):755-63. PMID: 24312145.
      Citations:    
    16. Mulshine JL. Advancing patient-centric genomic medicine. Oncology (Williston Park). 2013 Sep; 27(9):827. PMID: 24282976.
      Citations:    
    17. Warren GW, Marshall JR, Cummings KM, Toll BA, Gritz ER, Hutson A, Dibaj S, Herbst R, Mulshine JL, Hanna N, Dresler CA. Addressing tobacco use in patients with cancer: a survey of American Society of Clinical Oncology members. J Oncol Pract. 2013 Sep; 9(5):258-62. PMID: 23943904.
      Citations:    
    18. Mulshine JL, Ondrey FG. Not significant but important. Cancer Prev Res (Phila). 2013 May; 6(5):371-4. PMID: 23639860.
      Citations:    
    19. Jaklitsch MT, Jacobson FL, Austin JH, Field JK, Jett JR, Keshavjee S, MacMahon H, Mulshine JL, Munden RF, Salgia R, Strauss GM, Swanson SJ, Travis WD, Sugarbaker DJ. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg. 2012 Jul; 144(1):33-8. PMID: 22710039.
      Citations:    
    20. Field JK, Smith RA, Aberle DR, Oudkerk M, Baldwin DR, Yankelevitz D, Pedersen JH, Swanson SJ, Travis WD, Wisbuba II, Noguchi M, Mulshine JL. International Association for the Study of Lung Cancer Computed Tomography Screening Workshop 2011 report. J Thorac Oncol. 2012 Jan; 7(1):10-9. PMID: 22173661.
      Citations:    
    21. Tauler J, Zudaire E, Liu H, Shih J, Mulshine JL. hnRNP A2/B1 modulates epithelial-mesenchymal transition in lung cancer cell lines. Cancer Res. 2010 Sep 15; 70(18):7137-47. PMID: 20807810.
      Citations:    
    22. Mulshine JL, Baer TM, Avila RS. Introduction: Imaging in diagnosis and treatment of lung cancer. Opt Express. 2010 Jul 05; 18(14):15242-3. PMID: 20640010.
      Citations:    
    23. Chow G, Tauler J, Mulshine JL. Cytokines and growth factors stimulate hyaluronan production: role of hyaluronan in epithelial to mesenchymal-like transition in non-small cell lung cancer. J Biomed Biotechnol. 2010; 2010:485468. PMID: 20671927.
      Citations:    
    24. Mulshine JL, Jablons DM. Volume CT for diagnosis of nodules found in lung-cancer screening. N Engl J Med. 2009 Dec 03; 361(23):2281-2. PMID: 19955529.
      Citations:    
    25. Tauler J, Mulshine JL. Lung cancer and inflammation: interaction of chemokines and hnRNPs. Curr Opin Pharmacol. 2009 Aug; 9(4):384-8. PMID: 19570713.
      Citations:    
    26. Veronesi G, Bellomi M, Mulshine JL, Pelosi G, Scanagatta P, Paganelli G, Maisonneuve P, Preda L, Leo F, Bertolotti R, Solli P, Spaggiari L. Lung cancer screening with low-dose computed tomography: a non-invasive diagnostic protocol for baseline lung nodules. Lung Cancer. 2008 Sep; 61(3):340-9. PMID: 18308420.
      Citations:    
    27. Gandara DR, Aberle D, Lau D, Jett J, Akhurst T, Heelan R, Mulshine J, Berg C, Patz EF. Radiographic imaging of bronchioloalveolar carcinoma: screening, patterns of presentation and response assessment. J Thorac Oncol. 2006 Nov; 1(9 Suppl):S20-6. PMID: 17409997.
      Citations:    
    28. Mayburd AL, Martl?nez A, Sackett D, Liu H, Shih J, Tauler J, Avis I, Mulshine JL. Ingenuity network-assisted transcription profiling: Identification of a new pharmacologic mechanism for MK886. Clin Cancer Res. 2006 Mar 15; 12(6):1820-7. PMID: 16551867.
      Citations:    
    29. Mulshine JL. Chemoprevention of head and neck cancer. Clin Adv Hematol Oncol. 2005 Oct; 3(10):763-5. PMID: 16258484.
      Citations:    
    30. Mulshine JL. Clinical issues in the management of early lung cancer. Clin Cancer Res. 2005 Jul 01; 11(13 Pt 2):4993s-4998s. PMID: 16000602.
      Citations:    
    31. Lynch TJ, Bogart JA, Curran WJ, DeCamp MM, Gandara DR, Goss G, Henschke CI, Jett JR, Johnson BE, Kelly KL, Le Chevalier T, Mulshine JL, Scagliotti GV, Schiller JH, Shaw A, Thatcher N, Vokes EE, Wood DE, Hart C. Early stage lung cancer--new approaches to evaluation and treatment: conference summary statement. Clin Cancer Res. 2005 Jul 01; 11(13 Pt 2):4981s-4983s. PMID: 16000599.
      Citations:    
    32. Avis I, Mart?nez A, Tauler J, Zudaire E, Mayburd A, Abu-Ghazaleh R, Ondrey F, Mulshine JL. Inhibitors of the arachidonic acid pathway and peroxisome proliferator-activated receptor ligands have superadditive effects on lung cancer growth inhibition. Cancer Res. 2005 May 15; 65(10):4181-90. PMID: 15899809.
      Citations:    
    33. Man YG, Shen T, Weisz J, Berg PE, Schwartz AM, Mulshine JL, Sang QX, Nieburgs HE. A subset of in situ breast tumor cell clusters lacks expression of proliferation and progression related markers but shows signs of stromal and vascular invasion. Cancer Detect Prev. 2005; 29(4):323-31. PMID: 16122886.
      Citations:    
    34. Man YG, Zhang Y, Shen T, Zeng X, Tauler J, Mulshine JL, Strauss BL. cDNA expression profiling reveals elevated gene expression in cell clusters overlying focally disrupted myoepithelial cell layers: implications for breast tumor invasion. Breast Cancer Res Treat. 2005 Jan; 89(2):199-208. PMID: 15692763.
      Citations:    
    35. Mulshine JL, Neckers L. Epithelial-directed drug delivery: influence of formulation and delivery devices. Lung Cancer. 2004 Dec; 46(3):387-92. PMID: 15541828.
      Citations:    
    36. Hattery D, Hattery B, Chernomordik V, Smith P, Loew M, Mulshine J, Gandjbakhche A. Differential oblique angle spectroscopy of the oral epithelium. J Biomed Opt. 2004 Sep-Oct; 9(5):951-60. PMID: 15447016.
      Citations:    
    37. Ballaz S, Mulshine JL. The potential contributions of chronic inflammation to lung carcinogenesis. Clin Lung Cancer. 2003 Jul; 5(1):46-62. PMID: 14596704.
      Citations:    
    38. Mulshine JL, Smith RA, Field JK, Hirsch FR. Tobacco money: up in smoke? Lancet. 2002 Dec 14; 360(9349):1979-80; author reply 1981. PMID: 12493299.
      Citations:    
    39. Mulshine JL, Smith RA. Lung cancer. 2: screening and early diagnosis of lung cancer. Thorax. 2002 Dec; 57(12):1071-8. PMID: 12454304.
      Citations:    
    40. van Klaveren RJ, de Koning HJ, Mulshine J, Hirsch FR. Lung cancer screening by spiral CT. What is the optimal target population for screening trials? Lung Cancer. 2002 Dec; 38(3):243-52. PMID: 12445745.
      Citations:    
    41. Hirsch FR, Bunn PA, Dmitrovsky E, Field JK, Franklin WA, Greenberg RE, Hansen HH, Henschke CI, Rigas JR, Smith RA, Toennesen P, Mulshine JL. IV international conference on prevention and early detection of lung cancer, Reykjavik, Iceland, August 9-12, 2001. Lung Cancer. 2002 Sep; 37(3):325-44. PMID: 12234703.
      Citations:    
    42. Bastarrika G, Pueyo JC, Mulshine JL. Radiologic screening for lung cancer. Expert Rev Anticancer Ther. 2002 Aug; 2(4):385-92. PMID: 12647981.
      Citations:    
    43. Field JK, Brambilla C, Caporaso N, Flahault A, Henschke C, Herman J, Hirsch F, Lachmann P, Lam S, Maier S, Montuenga LM, Mulshine J, Murphy M, Pullen J, Spitz M, Tockman M, Tyndale R, Wistuba I, Youngson J. Consensus statements from the Second International Lung Cancer Molecular Biomarkers Workshop: a European strategy for developing lung cancer molecular diagnostics in high risk populations. Int J Oncol. 2002 Aug; 21(2):369-73. PMID: 12118333.
      Citations:    
    44. Mulshine JL, Hong S, Mart?nez A, Tauler J, Avis I, Tockman MS, De Luca LM, Placke ME, Cuttitta F. Moving to the routine management of pre symptomatic lung cancer. Lung Cancer. 2001 Dec; 34 Suppl 2:S1-5. PMID: 11720735.
      Citations:    
    45. Tockman MS, Mulshine JL. The early detection of occult lung cancer. Chest Surg Clin N Am. 2000 Nov; 10(4):737-49. PMID: 11091923.
      Citations:    
    46. Man YG, Martinez A, Avis IM, Hong SH, Cuttitta F, Venzon DJ, Mulshine JL. Phenotypically different cells with heterogeneous nuclear ribonucleoprotein A2/B1 overexpression show similar genetic alterations. Am J Respir Cell Mol Biol. 2000 Nov; 23(5):636-45. PMID: 11062142.
      Citations:    
    47. Hong SH, Ondrey FG, Avis IM, Chen Z, Loukinova E, Cavanaugh PF, Van Waes C, Mulshine JL. Cyclooxygenase regulates human oropharyngeal carcinomas via the proinflammatory cytokine IL-6: a general role for inflammation? FASEB J. 2000 Aug; 14(11):1499-507. PMID: 10928984.
      Citations:    
    48. Dahl AR, Grossi IM, Houchens DP, Scovell LJ, Placke ME, Imondi AR, Stoner GD, De Luca LM, Wang D, Mulshine JL. Inhaled isotretinoin (13-cis retinoic acid) is an effective lung cancer chemopreventive agent in A/J mice at low doses: a pilot study. Clin Cancer Res. 2000 Aug; 6(8):3015-24. PMID: 10955779.
      Citations:    
    49. Mulshine JL, Henschke CI. Prospects for lung-cancer screening. Lancet. 2000 Feb 19; 355(9204):592-3. PMID: 10696976.
      Citations:    
    50. Montuenga LM, Mulshine JL. New molecular strategies for early lung cancer detection. Cancer Invest. 2000; 18(6):555-63. PMID: 10923104.
      Citations:    
    51. Chaudhry A, Carrasquillo JA, Avis IL, Shuke N, Reynolds JC, Bartholomew R, Larson SM, Cuttitta F, Johnson BE, Mulshine JL. Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer. Clin Cancer Res. 1999 Nov; 5(11):3385-93. PMID: 10589749.
      Citations:    
    52. Hong SH, Avis I, Vos MD, Mart?nez A, Treston AM, Mulshine JL. Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors. Cancer Res. 1999 May 01; 59(9):2223-8. PMID: 10232612.
      Citations:    
    53. Foss FM, Raubitscheck A, Mulshine JL, Fleisher TA, Reynolds JC, Paik CH, Neumann RD, Boland C, Perentesis P, Brown MR, Frincke JM, Lollo CP, Larson SM, Carrasquillo JA. Phase I study of the pharmacokinetics of a radioimmunoconjugate, 90Y-T101, in patients with CD5-expressing leukemia and lymphoma. Clin Cancer Res. 1998 Nov; 4(11):2691-700. PMID: 9829731.
      Citations:    
    54. Moody TW, Leyton J, Martinez A, Hong S, Malkinson A, Mulshine JL. Lipoxygenase inhibitors prevent lung carcinogenesis and inhibit non-small cell lung cancer growth. Exp Lung Res. 1998 Jul-Aug; 24(4):617-28. PMID: 9659587.
      Citations:    
    55. Hida T, Leyton J, Makheja AN, Ben-Av P, Hla T, Martinez A, Mulshine J, Malkani S, Chung P, Moody TW. Non-small cell lung cancer cycloxygenase activity and proliferation are inhibited by non-steroidal antiinflammatory drugs. Anticancer Res. 1998 Mar-Apr; 18(2A):775-82. PMID: 9615719.
      Citations:    
    56. Mulshine JL, Zhou J, Treston AM, Szabo E, Tockman MS, Cuttitta F. New approaches to the integrated management of early lung cancer. Hematol Oncol Clin North Am. 1997 Apr; 11(2):235-52. PMID: 9137968.
      Citations:    
    57. Scott FM, Treston AM, Shaw GL, Avis I, Sorenson J, Kelly K, Dempsey EC, Cantor AB, Tockman M, Mulshine JL. Peptide amidating activity in human bronchoalveolar lavage fluid. Lung Cancer. 1996 Jun; 14(2-3):239-51. PMID: 8794407.
      Citations:    
    58. Zhou J, Mulshine JL, Unsworth EJ, Scott FM, Avis IM, Vos MD, Treston AM. Purification and characterization of a protein that permits early detection of lung cancer. Identification of heterogeneous nuclear ribonucleoprotein-A2/B1 as the antigen for monoclonal antibody 703D4. J Biol Chem. 1996 May 03; 271(18):10760-6. PMID: 8631886.
      Citations:    
    59. Johnson BE, Bridges JD, Sobczeck M, Gray J, Linnoila RI, Gazdar AF, Hankins L, Steinberg SM, Edison M, Frame JN, Pass H, Nesbitt J, Holden D, Mulshine JL, Glatstein E, Ihde DC. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine. J Clin Oncol. 1996 Mar; 14(3):806-13. PMID: 8622028.
      Citations:    
    60. Avis IM, Jett M, Boyle T, Vos MD, Moody T, Treston AM, Mart?nez A, Mulshine JL. Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J Clin Invest. 1996 Feb 01; 97(3):806-13. PMID: 8609238.
      Citations:    
    61. Zhou J, Jensen SM, Steinberg SM, Mulshine JL, Linnoila RI. Expression of early lung cancer detection marker p31 in neoplastic and non-neoplastic respiratory epithelium. Lung Cancer. 1996 Feb; 14(1):85-97. PMID: 8696723.
      Citations:    
    62. Shaw GL, Gazdar AF, Phelps R, Steinberg SM, Linnoila RI, Johnson BE, Oie HK, Russell EK, Ghosh BC, Pass HI, Minna JD, Mulshine JL, Ihde DC. Correlation of in vitro drug sensitivity testing results with response to chemotherapy and survival: comparison of non-small cell lung cancer and small cell lung cancer. J Cell Biochem Suppl. 1996; 24:173-85. PMID: 8806100.
      Citations:    
    63. Quinn KA, Unsworth EJ, Miller MJ, Mulshine JL, Cuttitta F. Biochemical characterization of mouse liver IBE1-amide immunoreactivity: limitations of antibody-based approaches for verification of peptide expression. Peptides. 1996; 17(5):881-3. PMID: 8844781.
      Citations:    
    64. Phelps RM, Johnson BE, Ihde DC, Gazdar AF, Carbone DP, McClintock PR, Linnoila RI, Matthews MJ, Bunn PA, Carney D, Minna JD, Mulshine JL. NCI-Navy Medical Oncology Branch cell line data base. J Cell Biochem Suppl. 1996; 24:32-91. PMID: 8806092.
      Citations:    
    65. Zia F, Jacobs S, Kull F, Cuttitta F, Mulshine JL, Moody TW. Monoclonal antibody alpha IR-3 inhibits non-small cell lung cancer growth in vitro and in vivo. J Cell Biochem Suppl. 1996; 24:269-75. PMID: 8806109.
      Citations:    
    66. Avis I, Mathias A, Unsworth EJ, Miller MJ, Cuttitta F, Mulshine JL, Jakowlew SB. Analysis of small cell lung cancer cell growth inhibition by 13-cis-retinoic acid: importance of bioavailability. Cell Growth Differ. 1995 May; 6(5):485-92. PMID: 7647031.
      Citations:    
    67. Kelley MJ, Mulshine JL. Anticancer antibodies for lung cancer. J Clin Oncol. 1994 Nov; 12(11):2519-20. PMID: 7818695.
      Citations:    
    68. Ihde DC, Mulshine JL, Kramer BS, Steinberg SM, Linnoila RI, Gazdar AF, Edison M, Phelps RM, Lesar M, Phares JC, et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol. 1994 Oct; 12(10):2022-34. PMID: 7931470.
      Citations:    
    69. Ebina M, Steinberg SM, Mulshine JL, Linnoila RI. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res. 1994 May 01; 54(9):2496-503. PMID: 7909277.
      Citations:    
    70. Green M, Brodin O, Choi N, Drings P, Ginsberg R, Gralla R, Johnson D, Mulshine J, Payne D, Ruffi? P. Pre-operative and post-operative treatments in stage III NSCLC. Lung Cancer. 1994 Mar; 10 Suppl 1:S15-7. PMID: 8087504.
      Citations:    
    71. Mulshine JL, Johnson BE, Gazdar AF, Shaw GL, Kramer BS, Mitsudomi T, Minna JD, Pass H, Phelps R, Ghosh B, et al. Integrated clinical and basic studies related to circumventing non-small cell lung cancer drug resistance. Lung Cancer. 1994 Mar; 10 Suppl 1:S73-81. PMID: 8087530.
      Citations:    
    72. Treston AM, Scott FM, Vos M, Iwai N, Mains RE, Eipper BA, Cuttitta F, Mulshine JL. Biochemical characterization of peptide alpha-amidation enzyme activities of human neuroendocrine lung cancer cell lines. Cell Growth Differ. 1993 Nov; 4(11):911-20. PMID: 8297797.
      Citations:    
    73. Szabo E, Mulshine J. Epidemiology, prognostic factors, and prevention of lung cancer. Curr Opin Oncol. 1993 Mar; 5(2):302-9. PMID: 8457617.
      Citations:    
    74. Mulshine JL, Treston AM, Brown PH, Birrer MJ, Shaw GL. Initiators and promoters of lung cancer. Chest. 1993 Jan; 103(1 Suppl):4S-11S. PMID: 8380133.
      Citations:    
    75. Kim J, Kaye FJ, Henslee JG, Shively JE, Park JG, Lai SL, Linnoila RI, Mulshine JL, Gazdar AF. Expression of carcinoembryonic antigen and related genes in lung and gastrointestinal cancers. Int J Cancer. 1992 Nov 11; 52(5):718-25. PMID: 1330929.
      Citations:    
    76. Tockman MS, Gupta PK, Pressman NJ, Mulshine JL. Considerations in bringing a cancer biomarker to clinical application. Cancer Res. 1992 May 01; 52(9 Suppl):2711s-2718s. PMID: 1563002.
      Citations:    
    77. Linnoila RI, Jensen SM, Steinberg SM, Mulshine JL, Eggleston JC, Gazdar AF. Peripheral airway cell marker expression in non-small cell lung carcinoma. Association with distinct clinicopathologic features. Am J Clin Pathol. 1992 Feb; 97(2):233-43. PMID: 1372146.
      Citations:    
    78. Mulshine JL, Linnoila RI, Jensen SM, Magnani JL, Tockman MS, Gupta PK, Scott FS, Avis I, Quinn K, Birrer MJ, et al. Rational targets for the early detection of lung cancer. J Natl Cancer Inst Monogr. 1992; (13):183-90. PMID: 1389692.
      Citations:    
    79. Linnoila RI, Mulshine JL, Steinberg SM, Gazdar AF. Expression of surfactant-associated protein in non-small-cell lung cancer: a discriminant between biologic subsets. J Natl Cancer Inst Monogr. 1992; (13):61-6. PMID: 1327036.
      Citations:    
    80. Treston AM, Mulshine JL, Cuttitta F. Control of tumor cell biology through regulation of peptide hormone processing. J Natl Cancer Inst Monogr. 1992; (13):169-75. PMID: 1389690.
      Citations:    
    81. Mitsudomi T, Steinberg SM, Nau MM, Carbone D, D'Amico D, Bodner S, Oie HK, Linnoila RI, Mulshine JL, Minna JD, et al. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene. 1992 Jan; 7(1):171-80. PMID: 1311061.
      Citations:    
    82. Quinn KA, Treston AM, Scott FM, Kasprzyk PG, Avis I, Siegfried JM, Mulshine JL, Cuttitta F. Alpha-amidation of peptide hormones in lung cancer. Cancer Cells. 1991 Dec; 3(12):504-10. PMID: 1668141.
      Citations:    
    83. Avis IL, Kovacs TO, Kasprzyk PG, Treston AM, Bartholomew R, Walsh JH, Cuttitta F, Mulshine JL. Preclinical evaluation of an anti-autocrine growth factor monoclonal antibody for treatment of patients with small-cell lung cancer. J Natl Cancer Inst. 1991 Oct 16; 83(20):1470-6. PMID: 1656058.
      Citations:    
    84. Mitsudomi T, Steinberg SM, Oie HK, Mulshine JL, Phelps R, Viallet J, Pass H, Minna JD, Gazdar AF. ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res. 1991 Sep 15; 51(18):4999-5002. PMID: 1654209.
      Citations:    
    85. Whang-Peng J, Knutsen T, Gazdar A, Steinberg SM, Oie H, Linnoila I, Mulshine J, Nau M, Minna JD. Nonrandom structural and numerical chromosome changes in non-small-cell lung cancer. Genes Chromosomes Cancer. 1991 May; 3(3):168-88. PMID: 1651103.
      Citations:    
    86. Fridman R, Giaccone G, Kanemoto T, Martin GR, Gazdar AF, Mulshine JL. Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. Proc Natl Acad Sci U S A. 1990 Sep; 87(17):6698-702. PMID: 2168554.
      Citations:    
    87. Dearing MP, Steinberg SM, Phelps R, Anderson MJ, Mulshine JL, Ihde DC, Johnson BE. Outcome of patients with small-cell lung cancer: effect of changes in staging procedures and imaging technology on prognostic factors over 14 years. J Clin Oncol. 1990 Jun; 8(6):1042-9. PMID: 2161447.
      Citations:    
    88. Mulshine JL, Treston AM, Natale RB, Kasprzyk PG, Avis I, Nakanishi Y, Cuttitta F. Autocrine growth factors as therapeutic targets in lung cancer. Chest. 1989 Jul; 96(1 Suppl):31S-34S. PMID: 2661168.
      Citations:    
    89. Mulshine JL, Natale RB, Avis I, Treston AM, Kasprzyk PG, Nakanishi Y, Sausville EA, Trepel JB, Cuttitta F. Autocrine growth factors and lung cancer. Cancer Treat Res. 1989; 45:107-22. PMID: 2577167.
      Citations:    
    90. Tockman MS, Gupta PK, Myers JD, Frost JK, Baylin SB, Gold EB, Chase AM, Wilkinson PH, Mulshine JL. Sensitive and specific monoclonal antibody recognition of human lung cancer antigen on preserved sputum cells: a new approach to early lung cancer detection. J Clin Oncol. 1988 Nov; 6(11):1685-93. PMID: 2846790.
      Citations:    
    91. Nakanishi Y, Mulshine JL, Kasprzyk PG, Natale RB, Maneckjee R, Avis I, Treston AM, Gazdar AF, Minna JD, Cuttitta F. Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro. J Clin Invest. 1988 Jul; 82(1):354-9. PMID: 2839551.
      Citations:    
    92. Minna JD, Cuttitta F, Battey JF, Mulshine JL, Linnoila I, Gazdar AF, Trepel J, Sausville EA. Gastrin-releasing peptide and other autocrine growth factors in lung cancer: pathogenetic and treatment implications. Important Adv Oncol. 1988; 55-64. PMID: 3042610.
      Citations:    
    93. Kasprzyk PG, Cuttitta F, Treston AM, Avis I, Nakanishi Y, Wong H, Walsh JH, Mulshine JL. Consideration of the chemistry of solid-phase matrix interaction leads to improved quantitation of neuropeptides. Ann N Y Acad Sci. 1988; 547:41-53. PMID: 3239893.
      Citations:    
    94. Nakanishi Y, Cuttitta F, Kasprzyk PG, Avis I, Steinberg SM, Gazdar AF, Mulshine JL. Growth factor effects on small cell lung cancer cells using a colorimetric assay: can a transferrin-like factor mediate autocrine growth? Exp Cell Biol. 1988; 56(1-2):74-85. PMID: 2846378.
      Citations:    
    95. Doyle LA, Cuttitta F, Mulshine JL, Bunn PA, Minna JD. Markedly different antibody responses to immunized small cell and non-small cell lung cancer cells. Cancer Res. 1987 Oct 01; 47(19):5009-13. PMID: 3040237.
      Citations:    
    96. Keenan AM, Weinstein JN, Mulshine JL, Carrasquillo JA, Bunn PA, Reynolds JC, Larson SM. Immunolymphoscintigraphy in patients with lymphoma after subcutaneous injection of indium-111-labeled T101 monoclonal antibody. J Nucl Med. 1987 Jan; 28(1):42-6. PMID: 3794811.
      Citations:    
    97. Weinstein JN, Eger RR, Covell DG, Black CD, Mulshine J, Carrasquillo JA, Larson SM, Keenan AM. The pharmacology of monoclonal antibodies. Ann N Y Acad Sci. 1987; 507:199-210. PMID: 3327413.
      Citations:    
    98. Spitalnik SL, Spitalnik PF, Dubois C, Mulshine J, Magnani JL, Cuttitta F, Civin CI, Minna JD, Ginsburg V. Glycolipid antigen expression in human lung cancer. Cancer Res. 1986 Sep; 46(9):4751-5. PMID: 2425958.
      Citations:    
    99. Hsu SM, Huang LC, Hsu PL, Ge ZH, Ho YS, Cuttita F, Mulshine J. Biochemical and ultrastructural study of Leu M1 antigen in Reed-Sternberg cells: comparison with granulocytes and interdigitating reticulum cells. J Natl Cancer Inst. 1986 Aug; 77(2):363-70. PMID: 3090338.
      Citations:    
    100. Minna JD, Battey JF, Brooks BJ, Cuttitta F, Gazdar AF, Johnson BE, Ihde DC, Lebacq-Verheyden AM, Mulshine J, Nau MM, et al. Molecular genetic analysis reveals chromosomal deletion, gene amplification, and autocrine growth factor production in the pathogenesis of human lung cancer. Cold Spring Harb Symp Quant Biol. 1986; 51 Pt 2:843-53. PMID: 3472765.
      Citations:    
    101. Cuttitta F, Carney DN, Mulshine J, Moody TW, Fedorko J, Fischler A, Minna JD. Autocrine growth factors in human small cell lung cancer. Cancer Surv. 1985; 4(4):707-27. PMID: 2445479.
      Citations:    
    102. Mulshine JL, Makuch RW, Johnston-Early A, Matthews MJ, Carney DN, Ihde DC, Cohen MH, Bates HR, Dunnick NR, Minna JD, et al. Diagnosis and significance of liver metastases in small cell carcinoma of the lung. J Clin Oncol. 1984 Jul; 2(7):733-41. PMID: 6330314.
      Citations:    
    103. Rosen ST, Mulshine JL, Cuttitta F, Fedorko J, Carney DN, Gazdar AF, Minna JD. Analysis of human small cell lung cancer differentiation antigens using a panel of rat monoclonal antibodies. Cancer Res. 1984 May; 44(5):2052-61. PMID: 6713399.
      Citations:    
    104. Mulshine J, Lucas FV, Clough JD. Platelet-bound IgG in systemic lupus erythematosus with and without thrombocytopenia. J Immunol Methods. 1981; 45(3):275-81. PMID: 7288196.
      Citations:    
    Mulshine's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (487)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _